Goals
The burden of cancer affects a country's economy because of absence from work, lost productivity and premature mortality.
An assessment of the productivity lost due to premature death from cancer in Brazil, China, India, the Russian Federation and South Africa in 2012 indicated a loss of US$ 46.3 billion, corresponding to 0.2-0.5%
of total gross domestic product (GDP) in those countries (30). In 2009, the total cost of premature mortality related to cancer in Europe was estimated to be
€945.7 million (31). Countries with UHC can protect people against such negative economic and social consequences and improve their outcomes (23).
While substantial progress has been made in HIC because of favourable trends in cancer incidence and mortality attributed directly to advances in cancer control, progress in LMIC has been slow and insufficient (32, 33) (Fig. 1.10) and must be accelerated.
Section I 34
Global AFR AMR EMR EUR SEAR WPR 2%
6%
4%
Probability of premature death
8%
10%
High-income (HIC) Low-income
(LIC) Middle-income (MIC)
2000 2015 2030 Projected 2030 Target
Fig. 1.10. Progress toward SDG target 3.4. Change between 2000 and 2015 in probability of dying from cancer during ages 30-69 years of age and trend toward 2030, by Region and World Bank income level.
Source: reference 1
References
1. Global Health Observatory. Geneva: World Health Organization; 2016 (http://www.who.int/gho/
database/en/ accessed [date]).
2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: cancer today, Lyon: International Agency for Research on Cancer; 2019.
3. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: cancer tomorrow. Lyon: International Agency for Research on Cancer; 2019.
4. NCD Countdown 2030 collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 2018;392(10152):1072 -88.
5. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018;68 (6):394 -424.
6. Human Development Index. New York City (NY): United Nations Development Programme;
2020 (http://hdr.undp.org/en/content/human-development-index-hdi, accessed January 2020).
7. Bray F, Moller B. Predicting the future burden of cancer. Nature Rev Cancer. 2006;6 (1):63 -74.
8 Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008 -2030): a population-based study. Lancet Oncol. 2012;13(8):790 -801.
9. World population prospects. New York City (NY): United Nations; 2019 (https://population.un.org/
wpp/, accessed January 2020).
10. Lam CG, Howard SC, Bouffet E, Pritchard-Jones K. Science and health for all children with cancer.
Science. 2019;363(6432):1182 -6.
11. CI5plus. Cancer Incidence in Five Continents time trends. Lyon: International Agency for Research on Cancer; 2020 (http://ci5.iarc.fr/CI5plus/Pages/graph1_sel.aspx, accessed January 2020).
12. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000 -14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.
Lancet. 2018;391(10125):1023 -75.
13. Bryere J, Dejardin O, Launay L, Colonna M, Grosclaude P, Launoy G, et al. Socioeconomic status and site-specific cancer incidence, a Bayesian approach in a French Cancer Registries Network study. Eur J Cancer Prev. 2018;27(4):391 -8.
14. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–e190.
doi:10.1016/S2214-109X(19)30488-7
15. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4 (7):e453 -63.
16. Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378 (11):1029 -41.
17. Stanbury JF, Baade PD, Yu Y, Yu XQ. Cancer survival in New South Wales, Australia: socioeconomic disparities remain despite overall improvements. BMC Cancer. 2016;16:48.
18. Aarts MJ, Kamphuis CB, Louwman MJ, Coebergh JW, Mackenbach JP, van Lenthe FJ. Educational inequalities in cancer survival: a role for comorbidities and health behaviours? J Epidemiol Community Health. 2013;67 (4):365 -73.
19. Brand NR, Qu LG, Chao A, Ilbawi AM. Delays and barriers to cancer care in low- and middle-income countries: a systematic review. Oncologist. 2019;24 (12):e1371 -80.
20. Bakens M, Lemmens V, de Hingh I. Socio-economic status influences the likelihood of undergoing surgical treatment for pancreatic cancer in the Netherlands. HPB (Oxford). 2017;19(5):443 -8.
21. Foerster M, Anderson BO, McKenzie F, Galukande M, Anele A, Adisa C, et al. Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study. Breast Cancer Res. 2019;21(1):93.
22. Bergeron-Boucher MP, Oeppen J, Holm NV, Nielsen HM, Lindahl-Jacobsen R, Wensink MJ.
Understanding differences in cancer survival between populations: a new approach and application to breast cancer survival differentials between Danish regions. Int J Environ Res Public Health. 2019;16(17).
23. Maruthappu M, Watkins J, Mohd Noou A, Williams C, Ali R, Sullivan R, et al. Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990 -2010: a longitudinal analysis. Lancet. 2016;388(10045):684 -95.
24. Choi JW, Cho KH, Choi Y, Han KT, Kwon JA, Park EC. Changes in economic status of households associated with catastrophic health expenditures for cancer in South Korea. Asian Pac J Cancer Prev. 2014;15(6):2713 -7.
25. Ilbawi A, Meheus F. Universal health coverage. Chapter 40. In: Jemal A, Torre L, Soerjomataram I, Bray F, editors. The cancer atlas, 3rd edition. New York City (NY): American Cancer Society; 2019 (https://canceratlas.cancer.org/taking-action/universal-health-coverage/, accessed January 2020).
26. Leng A, Jing J, Nicholas S, Wang J. Catastrophic health expenditure of cancer patients at the end-of-life: a retrospective observational study in China. BMC Palliat Care. 2019;18(1):43.
27. Ramsey SD, Bansal A, Fedorenko CR, Blogh DK, Overstreet KA, Shankararan V, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol.
2016;34(9):980 -6.
28. Romito F, Goldzweig G, Cormio C, Hagedoorn M, Andersen BL. Informal caregiving for cancer patients. Cancer. 2013;119(Suppl 11):2160 -9.
29. Mailhot Vega RB, Balogun OD, Ishaq OF, Bray F, Ginsburg O, Formenti SC. Estimating child mortality associated with maternal mortality from breast and cervical cancer. Cancer.
2019;125(1):109 -17.
30. Pearce A, Sharp L, Hanly P, Barchuk A, Bray F, de Camargo Cancela M, et al. Productivity losses due to premature mortality from cancer in Brazil, Russia, India, China, and South Africa (BRICS):
a population-based comparison. Cancer Epidemiol. 2018;53:27 -34.
31. Hanly PA, Sharp L. The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer. 2014;14:224.
32. Cao B, Bray F, Ilbawi A, Soerjomataram I. Effect on longevity of one-third reduction in premature mortality from non-communicable diseases by 2030: a global analysis of the Sustainable Development Goal health target. Lancet Glob Health. 2018;6(12):e1288 -96.
33. Cao B, Bray F, Beltran-Sanchez H, Ginsburg O, Soneji S, Soerjomataram I. Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981 -2010.
BMJ. 2017;357:j2765.
Section I 36